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Background: Next Generation Sequencing (NGS) is expected to help find the elusive, causative genetic defects
associated with Bipolar Disorder (BD). This article identifies the importance of NGS and further analyses the social
and ethical implications of this approach when used in research projects studying BD, as well as other psychiatric
ailments, with a view to ensuring the protection of research participants.
Methods: We performed a systematic review of studies through PubMed, followed by a manual search through
the titles and abstracts of original articles, including the reviews, commentaries and letters published in the last five
years and dealing with the ethical and social issues raised by NGS technologies and genomics studies of mental
disorders, especially BD. A total of 217 studies contributed to identify the themes discussed herein.
Results: The amount of information generated by NGS renders individuals suffering from BD particularly vulnerable,
and increases the need for educational support throughout the consent process, and, subsequently, of genetic
counselling, when communicating individual research results and incidental findings to them. Our results highlight
the importance and difficulty of respecting participants’ autonomy while avoiding any therapeutic misconception.
We also analysed the need for specific regulations on the use and communication of incidental findings, as well as
the increasing influence of NGS in health care.
Conclusions: Shared efforts on the part of researchers and their institutions, Research Ethics Boards as well as
participants’ representatives are needed to delineate a tailored consent process so as to better protect research
participants. However, health care professionals involved in BD care and treatment need to first determine the
scientific validity and clinical utility of NGS-generated findings, and thereafter their prevention and treatment
significance.
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The use of Next Generation Sequencing (NGS) tech-
nologies is expected to greatly facilitate the discovery
of many – up till now elusive – causative genes for, and
gene variants of, complex trait conditions. Past genetic
studies into bipolar disorder (BD) have been char-
acterized by low reproducibility and inconclusive find-
ings [1]. Reasons include a combination of multigenic* Correspondence: beatrice.godard@umontreal.ca
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reproduction in any medium, provided the orbackground and environmental factors, which them-
selves contribute to a wide range of phenotypic expres-
sions of this condition.
In comparison with traditional sequencing, the use of
NGS is regarded as ideal to discover genetic mutations
and gene expression variations causative of BD because
of the amount and diversity of genetic variants these
technologies can reveal [1].
Given the important social and economic burden of
BD throughout the world, finding factors that not only
help better understand individual predisposition to this
condition, but also better prevent the potential harmsral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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ciated with the risks of erroneous diagnosis and inappro-
priate therapy will have an enormous social impact. The
importance of addressing related ethical issues in con-
cert with efforts to identify such genetic risk factors lies
in maximizing health benefits to those affected by this
disease while minimizing negative social implications.
The use of NGS in research can provide a great
amount of new information, which, at times, is unrelated
to the issue that first prompted the study. This has con-
sequences for scientists and their institutions as well as
for research participants – inasmuch as there is unex-
pected information to be dealt with. Researchers are
faced with either providing it, or not, and participants
with receiving it – or not. BD patients are in a fairly vul-
nerable position [2] with regard to the significance of
results, the difficulty of understanding complex individ-
ual findings and, most importantly, because of the im-
pact that learning these results may have on their lives.
The latter is heightened in genetic research.
The protection of NGS study participants calls for spe-
cific approaches on preserving autonomy, disclosing
results and communicating incidental findings [3,4].
However, protocols that address the genetics of mental
disorders may well need supplementary social and eth-
ical safeguards for vulnerable populations whose quality
of life could greatly benefit from finding underlying
causes for their conditions and the development of ap-
propriate treatments.
This article provides a review of the application of
NGS to complex traits and its challenges with BD. We
discuss the social and ethical implications of the use of
NGS in research from the perspective of protecting par-
ticipants in genetic research protocols directed to sub-
jects with BD. Our approach covers both research and
emergent clinical settings requiring special attention.
Methods
In order to determine the social and ethical issues cur-
rently reviewed in the literature related to the identifica-
tion of gene factors associated with BD, we first
performed a systematic review of studies published in
the last five years on the ethical, legal and social issues
raised by: (1) new genome sequencing approaches, such
as NGS, whole exome sequencing, genome-wide associ-
ation studies, or whole genome sequencing, and (2) gen-
etics and genomics studies on mental disorders,
especially on bipolar spectrum disorders. Studies for po-
tential inclusion were identified through a PubMed
search, using different combinations of keywords, fol-
lowed by a manual search. The search was limited to
titles and abstracts of original articles, reviews, commen-
taries and letters. A total of 217 studies were relevant to
our project and constituted the sample upon which weperformed a detailed analysis of the ethical issues raised
by NGS when it is applied to mental disorders, and in
particular to BD.
Results
NGS in research applied to complex traits
DNA sequencing technologies involving high-through-
put, low-cost procedures are expected to greatly help in
finding new genomic variations associated with a wide
variety of diseases. They are also regarded as the key to
comprehending those of multivariate genetic origin [5].
Different alternatives are currently being considered.
While the use of Whole Genome Sequencing (WGS) of
large patient cohorts is a much-needed approach in
complex traits research, so as to detect low frequency
genetic variants, it is still being ruled out, due to its high
costs [6,7]. Lower-cost possibilities include gene-targeted
sequencing, partial sequencing of pooled samples and
exome sequencing [6]. The latter is currently the least
expensive and a highly reliable alternative to WGS in
uncovering genetic defects associated with various com-
plex traits, particularly when combined with sequencing
exome flanking non-coding regions [8,9]. Sanger sequen-
cing of these additional regions has also shown their sig-
nificance [10]. Some genetic variants will be absent or
underrepresented using this approach, since approxi-
mately 15% of patients with a genetically predisposed
condition do not have coding sequence mutations [5].
The application of NGS techniques in research settings
appears to be effective, although it displays a number of
technical and analytical challenges, ranging from the
storing and handling of data or mapping and under-
standing genetic variations, to differentiating errors and
variants of different frequency [6]. Awareness of these
issues contributes to the acceptance that complete ac-
curacy is not possible [5,11] and that errors originating
in a research context could be reflected in, and trans-
ferred to, clinical applications of experimental results.
Any consent process for genetic studies using these
methodologies and considering communication of re-
search results and incidental findings has to be clear on
the limitations of these procedures. It is just as import-
ant that health care workers and patients seeking
answers about these conditions understand the uncer-
tainties of any possible clinical applications based on
results obtained from this technology. We address these
issues in detail later in this paper.
Reasons for diversity
Past genetic studies of complex-trait psychiatric disor-
ders using linkage and association studies have been
characterized by low reproducibility and insufficient
findings [1]. Two main, recurring aspects of flawed
results, i.e., sample size and participant heterogeneity,
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participants diagnosed with BD [12]. While the genotyp-
ing of very large samples is expected to be an easily
overcome obstacle as NGS becomes more affordable, the
heterogeneity of BD subjects remains problematic. BD
present a range of subtypes, and the medical diagnostic
process itself could be a source of considerable variation
[12]. However, the cause of sample heterogeneity, and
the reason for the wide range of subtypes in BD and
other psychiatric conditions could simply be due to par-
ticipants’ diverse genetic backgrounds. That is, the same
phenotype, or, in other words, the same disease diagno-
sis, is caused by many genes, or by multiple variants of
the same gene(s) [1].
Different and perhaps concurrent scenarios that may
help explain BD genetic and phenotypic diversity could
be the existence of interactions among genes that are
overlooked when genes and gene variants are examined
separately; the presence of copy number variants (CNV)
that modify how much of the same gene an individual
carries – a presence, therefore, that changes the “nor-
mal” array of protein-protein and gene-protein interac-
tions; or, still, the variable penetrance of different
mutations, in addition to epigenetic changes, which
themselves have been causally linked to psychiatric con-
ditions [1,13,14]. This description is indeed common to
complex genetic disorders [15].
The application of NGS technology to large scale gen-
etic studies and to small distinctive groups of affected
individuals [6] could help identify the many variants that
may be simultaneously involved in the different
spectrum conditions of BD and in populations of
different ethnic backgrounds. Linkage, association and
candidate gene approach studies conducted on families,
unrelated individuals, and on individuals showing
extremes or particular phenotypes of BD have demon-
strated that the selection of small distinctive groups of
affected individuals could enhance genetic study results
[12,16]. Although many of these studies have shown low
reproducibility in the past, it is believed the situation
would improve if DNA samples of these same cohorts
were to be evaluated without predetermined analysis or
targeted sequences [5,6,9]. It remains paradoxical that
even though patient phenotype heterogeneity remains an
issue to be resolved, that very phenotype is at the same
time the basis for participant selection when searching
for the genetic foundations of BD.
Disease phenotype
Sample selection is important when seeking to highlight
genetic differences that underlie a given condition. Yet it
is also influenced by an individual’s desire to participate
in genetic research. Some patients with various psychi-
atric, genetically-based disorders are more inclined thanothers to seek treatment and to volunteer for clinical
studies [17]. While the grounds for this distinctive be-
haviour are not clear, the behaviour itself may be influ-
enced by a variety of reasons. For instance, identifying
genetic ethnic differences between Caucasian and Afri-
can American Bipolar patients could provide great diag-
nostic tools for BD [18]. However, fears of racial
discrimination, social stigmatization and the breach of
privacy associated with mental illness may prompt
patients to decide against participation in a genetic
study, whatever their ethnic background. Socioeconomic
factors such as access to medical, social and financial
support or the lack thereof may change a patient’s per-
ception about participating in a research project [19].
Unemployment and health problems are reportedly
more frequent with BD than with other psychiatric con-
ditions [20]. Thus, compensation for participation, either
monetary or through the greater availability of much-
needed treatment, and provided as part of a study’s
protocol when otherwise not readily accessible, could be
enticing to some individuals, whereas the fear of social
stigmatization may deter others from participating in a
given research project [2,19]. Taking into account the
multifaceted genetic bases of psychiatric disorders, the
diverse motivations behind patient participation, or non-
participation, in genetic studies, affects the availability of
data about the relevant genetic variants which contribute




Informed consent is one of the most basic elements in
the protection of human subjects involved in research
projects. While the ultimate goal is facilitating an
informed and autonomous decision on participating in
research, the intricacy of the protocols and the complex-
ity of the type and later uses of information derived from
research require a degree of comprehension that renders
many individuals quite vulnerable [2].
Whenever people consent to participate in genetic re-
search, issues such as the scientific bases of the research
project, participants’ cultural values and the social pos-
ition of the targeted study population become particu-
larly relevant [21].
Clear appreciation of the science behind a research
protocol could well change the perception of the issue
prompting the research study, reducing misunderstand-
ings and potential feelings of stigmatization. In the gen-
eral population, degrees of comprehension of research
issues correlate with levels of literacy and thus with the
capacity to better understand the goals, risks and use of
study-generated results. That, in turn, is linked to differ-
ential health care resources [21]. Lower literacy [21] and
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individuals living with mental health disorders [20] – are
in many places associated with restricted access to
health care. In such circumstances, access to the
genetic counselling necessary to fully understand
genetic research results becomes more difficult [21].
Grasping even more complex outcomes, such as those
derived from NGS technologies, becomes increasingly
problematic.
In terms of the capacity to comprehend the issue that
prompts a genetic study and the recourse to NGS, men-
tal health disorders present variable cognitive impair-
ments that can vary over time and between individuals
(i.e., “more severe in mania and schizophrenia than per-
sonality disorders” [22]). Cognition varies according to a
patient’s status at time of consultation. Cognitive impair-
ment has been observed at all stages of BD while
decision-making abilities appeared weakened during
manic as opposed to euthymic phases [23-25]. Cognition
impairment is linked to the effects of medication and
the length of the euthymic phase at time of patient
evaluation [23,25]. Owen et al. [22] and van der Baan
et al. [26] examined the significance of patients’ dimin-
ished cognition and how it impacted both treatment
decisions [22] and the capacity to give informed consent
on sample biobanking for pharmacogenetic studies in
psychiatric wards [26]. Decisions on treatment are an
imperative in most clinical settings. In many instances,
this requirement may possibly be extended to an
imminent decision to participate in pharmacogenetic
studies when evaluation of drug response relies on genes
and gene expression analyses that need baseline sam-
pling or a potential treatment modification decision. The
latter may coincide with the need to obtain consent for
sample banking procedures [26]. In which case patients
experiencing a highly diminished capacity to consent
[26] could be asked to understand and decide on the
implications of current genetic research technology.
Distinct protective measures should be put in place for
any consent process involving NGS technologies and
BD, as well as analogous ailments, because of patients’
and participants’ cognitive variability: measures such as
educational activities [26,27], the presence of specially-
trained personnel [26], and an increased availability of
genetic counselling when explaining the purpose of the
study and/or the return of genetic results. The extended
use of genetic counselling, as reviewed by Bunnik et al.
[28], is justified by “The potentially greater psychological
impact of genetic testing for psychiatric diseases. . .”
when compared to somatic conditions [28]. We consider
that these measures would be decisive in enhancing
patients’ and participants’ decision-making capacity.
As discussed by van der Baan et al. [26], appropriate
consent forms should be based on opt-in systems so asto safeguard individual autonomy and maintain the in-
tegrity of research projects.
Risks to participants
The consent process considers the impact of research
results on the life of participants, on their families and
their communities, in particular when the targeted
population is an identifiable ethnic minority [21]. These
notions have an increased significance in research proto-
cols aimed at discerning genetic predisposition to psy-
chiatric conditions, due to the stigma associated with
the latter. Stigma, as discussed by Bunnik et al. [28], may
lead to a troubled social life and “discrimination at the
work place”.
On consent forms, two risk categories are classified as
separate entities, loss of privacy and misuse of informa-
tion [29], on the one hand, and potential medical and
physical harms, on the other. Yet both are interrelated,
as study results conveyed with insufficient caution, or
the misuse of results through the provision, either of in-
complete or wrong information, or one causing a loss of
privacy, may themselves cause medical and physical
harm by influencing participants’ ultimate behaviour –
of particular concern in psychiatric disorders. Receiving
results indicating a predisposition to a psychiatric dis-
order could initiate the expression of first symptoms
[28], or could well affect self-image, increase anxiety or
induce depression [28,30].
Explanations on confidentiality, participants’ rights of
withdrawal and specifications of future use have a differ-
ent relevance in genetic studies in general, and in the ap-
plication of NGS, in particular [29]. Data sharing is the
basis of current genetic analysis, which limits the possi-
bility of withdrawing, and gives a different perspective to
confidentiality, as data and samples may be used under
diverse jurisdictions, and future use of data (and sam-
ples) becomes complex, because increased knowledge
about genetic predisposition shows the intricate relation-
ship between different conditions in addition to generat-
ing unsuspected findings. Recent examples are the
identification of a previously unknown causative muta-
tion of idiopathic haemolytic anaemia as a result of
studying ADHD familial inheritance [31], as well as a
common SNP related to comorbid migraine in indivi-
duals suffering from BD and ADHD [16].
Protecting participants
There is a general consensus that the consent process
should include an explanation about how information
will be handled [3]. How best to ensure protection of the
individual and overcome the challenges of respecting
confidentiality, the right to withdraw and the proper use
of materials and data? It may require the establishment
of governance structures involving institutions, Research
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active input from all parties involved. In addition, a
streamlined governance would facilitate tracking the
proper use of the great amount of data generated by
NGS [29]. We agree with other commentators [4] that
input from patients’ representatives and study partici-
pants would add the perspective of those individuals
most likely to benefit from subsequent research findings.
However, we consider that the timing of their participa-
tion may vary, as discussed below, in the case of BD, and
psychiatric disorders in general. While protective mea-
sures as to future use are being established, it is possible
to seek a broad consent implying permission for even-
tual applications, an option already in use in oncology
settings [32]. Two other options, keeping genetic re-
search closer to the subject of the original consent, or
obtaining a new, updated consent from research partici-
pants [33], are also legitimate.
Feedback, return of results and incidental findings
The question of how to determine what feedback [5] BD
research participants should receive about their genomes
brings to light the importance of providing measures to
protect research participants, their families and commu-
nities, considering “the societal and psychological sensi-
tivities that surround psychiatric diseases” [28].
Results can vary in their levels of direct relevance to
the issue that prompted the research project at the out-
set, while incidental findings are generated faster than,
in many cases, they can be understood. Return of indi-
vidual results have been part of the consent process in
various oncology settings for some time [32]. It is clear
that some areas of research are more closely linked to a
therapeutic component than others, making return of in-
dividual results easier and more significant. Age of onset,
available therapies and preventive treatments for a given
health condition should be used to evaluate the ethical
implications of returning research results, incidental or
otherwise, in particular when mental health is part of
the equation. For instance, using these parameters,
Bunnik et al. [28] clearly differentiate the psychological
and social risks of using genetic test results to convey
predisposition to diabetes, age-related macular degener-
ation and clinical depression. Their results highlight the
negative impact on disease progression when these three
factors are not clearly defined at the time of sharing
results [28].
As for individual wishes and personal motivations
for participating in research, another study found that
parents of autistic children showed a strong desire to re-
ceive research results, independently of their nature,
meaning, or relation to the reason that first prompted
the study [34]. Although their understanding of the dif-
ference between research and clinical settings was clearlystated, their expressed wish for feedback was associated
with feelings of “relief, understanding and preparation
for the future” [34]. It thus becomes apparent that those
who participate in research protocols seek in some way
to better understand their condition. Return of individ-
ual results may thus distort the aim of the research by
generating therapeutic misconception [32].
In Misra et al., BD patients were questioned on their
role as research participants. They misunderstood the
notions of therapeutic care and research [2], illustrating
that participants in BD research protocols can be more
vulnerable to therapeutic misconception and can lack
autonomous decision-making power. In other words,
offering to return research results – independently of
their nature – could further heighten the confusion sur-
rounding the difference between research and clinical
practice in this population if not accompanied by ad-
equate education and counselling.
A way of respecting participants’ autonomy would be
to disclose results in a tailored fashion, following options
that Research Ethics Boards (REBs), together with parti-
cipants and researchers, could choose, according to the
subject matter and the social group targeted by the study
[4,21]. It has been argued that the promise of returning
individual research results will increase the work load
for both researchers and the research infrastructure [4].
This becomes particularly true when including the costs
of associated genetic counselling. Therefore, recommen-
dations, such as those set forth in the Tri-Council Policy
Statement (TCPS) [35], to employ genetic counselling to
communicate genetic research findings, may ultimately
lead researchers to restrict the communication of indi-
vidual research findings derived from the use of NGS.
The return of individual results is a subject of debate
in many fields of research. In Canada, the TCPS pro-
motes the communication of all material, incidental
findings that have “significant welfare implications for
the participant, whether health-related, psychological or
social” [35]. No such recommendation is made when the
study tools are designed for research and have no bear-
ing on clinical diagnosis [29]. The NGS technologies
currently used and developed in various research set-
tings do not respond to standards and validation pro-
cesses required for and followed by procedures in
clinical practice [29]. Bredenoord et al. explained that al-
though these positions are contradictory, opposing
standpoints regarding the disclosure of incidental find-
ings nonetheless keep the basic human principal of sav-
ing a life paramount [3].
There is, however, a basic ethical principle that should
prevail, independently of the governance that guides the
process of returning results and incidental findings: an
evaluation of the risk-benefit ratio for the individual re-
ceiving the information. While understanding the
Groisman et al. BMC Medical Ethics 2012, 13:36 Page 6 of 9
http://www.biomedcentral.com/1472-6939/13/36benefits seems a simple process, the extent of the risks of
communicating incidental findings to individuals and
families affected by mental health disorders, risks such as
uninsurability [36], stigmatization [28], unpredictable
discrimination, and loss of social support, are not always
evident. Even when participants are willing to be
informed individually, regardless of the nature of the re-
search results [34], the consent process would have to be
clear enough to explain to what extent being informed of
some outcomes could jeopardize their future.
There appears to be a clear necessity for governance,
proper policies and procedures [33], based on the needs
and characteristics of different social groups, to manage
whether or what information is conveyed to them
[3,4,29]; to whom it should be communicated, i.e., to
individuals alone or also to families and physicians
[29,37]; who is responsible for returning results, solely
the investigator conducting the original research or
equally those using the data and samples as secondary
research material [29]? The direct involvement of insti-
tutions and their Research Ethics Boards could be cru-
cial in handling this process [29,33].
Finally, the return of research results is deemed im-
portant from a societal standpoint, inasmuch as it con-
tributes to building trust toward research endeavours
[29]. However, it is imperative to differentiate results
that are public from those conveyed to individuals,
whether they be incidental results or ones prompted by
the object of research. With an increasing awareness of
consumer genetic testing, individuals may gain a differ-
ent perception of genetic “research” and thus, their
views as study participants could possibly change [29].
Previous reports indicate that individuals with mental
disorders and their immediate relatives are more prone
to undergo genetic testing to determine their disease
susceptibility [30,38]. This tendency, in addition to the
cognitive impairment associated with mental health con-
ditions, could help explain the possible confusion in rea-
sons given by individuals to become research
participants, and strengthens the need for additional
educational efforts at time of recruitment. The expecta-
tions of those who take part in research protocols with
the sole purpose of helping others have to be distin-
guished from those that hope to obtain genetic informa-
tion about themselves [29]. The research community is
indebted to the altruistic group, while the second one
should be considered as a clientele of genetic products
and reminded of the exact goals of any research project.
Informed decision-making and autonomy
There is a very close link between the return of research
results and participant autonomy. As discussed above,
individuals are selected based on a phenotype for which
a genetic cause is not known or because of the intuitionthat an underlying genetic factor may explain their
phenotype. It is on these bases that individuals are regu-
larly invited to participate as subjects in research pro-
jects, and, if they accept, asked if they want to know
some, or all of the findings, and if they allow the latter
to be shared. While P. Bielby explained that the consent
process must not have an external form of control, so as
to avoid any possible coercion [39], Misra et al. showed
that “. . . over half of all subjects believed that their pri-
mary mental health provider could convince them to
participate even if they did not want to” [2].
In genetic studies it is possible that a gene associated
with a disease phenotype may be discovered while its
function is not yet understood, and thus there are no
prevention or treatment possibilities [11]. The applica-
tion of NGS would lead not only to the discovery of
causative gene-diseases but also to the identification of
countless mutations unrelated to the original goal of the
study, and that could yet have health implications for
the individual participants, their immediate family and
their offspring [11,29]. As previously discussed [39],
competence to consent to participate in research implies
“that an individual receive sufficient information in
order to make that decision in an appropriate way”.
However, it is in a context of vague knowledge that
researchers ask participants to decide “autonomously”
on what it is they want to know, or not know.
Different solutions have been proposed to help respect
the basic principles of decision-making and autonomy.
One possibility consists of giving individuals the choice
of knowing only part of the results, for example by re-
ceiving information solely on gene mutations leading to
preventable or treatable disorders at the time of discov-
ery, whether related or not to the subject that prompted
the study [4]. In the case of minors, information about
those conditions medically relevant to their particular
age is a valid alternative. The option of receiving differ-
ent information at successive life stages is also legitim-
ate, although it requires special procedures and
resources to store and retrieve data [11], all the while
safeguarding participants’ confidentiality and, thus, in-
creasing researchers’ responsibilities [4]. The option of
not providing any tests results at all [11] does not com-
ply with regulations that seek to promote the communi-
cation of all “material incidental significant findings”,
such as the TCPS [35]. This dichotomy has practical
solutions at the level of the REBs, when implementing
different “consent packages” or considering alternatives
for the return of results [4,33].
Clinically relevant ethical challenges
While the influence of NGS increases, there is a need to
examine how it may modify health care practices and
what new clinical and ethical challenges may arise.
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NGS technologies in clinical settings for BD, by allowing,
for instance, early intervention and, thus, presenting –
as described by Leopold et al. – the prospect of reducing
the symptomatology and diminishing the negative life
consequences that are attached to this condition [20].
NGS could increase the capacity to quickly scan a genome
in the search for potential genes, mutations or variations,
allowing for better stratification and validation, thus
leading to better defined BD subgroups. More reliable and
earlier diagnostic tools could then be developed,
permitting the development of new and individualized
therapies, optimizing treatment responses. However, there
are potential socio-ethical risks associated with these
expected clinical benefits, such as risks of biohype,
therapeutic misconception, genetic exceptionalism vs.
denial of the genetic component by individuals who do
not have the coding sequence mutations, a lack of genetic
counselling resources, a lack of education among health
professionals, a lack of social support, inequity of access to
health care services, or, still, stigmatization, without
forgetting that society’s willingness to pay high costs for
drugs is becoming increasingly doubtful.
Initial symptoms of BD may appear as early as mid-
adolescence, with a higher prevalence of mood and non-
mood disorders in offspring of BD parents as compared
to a control population [40]. Tools to define very early
signs of the disease would help distinguish different BD
subtypes and select proper treatment [20]. We agree
with previous reports [20] that the improvement of
adolescents’ and young adults’ quality of life, by facili-
tating completion of studies and strengthening family
and social ties, will decrease stigma and increase the
social support needed to cope with BD. Based on age
of onset and the need to determine early signs of BD,
we infer that NGS will impact child, adolescent and
adult clinical settings, the latter probably because of
the quest for more personalized therapies and the de-
sire to know the genetic susceptibility of their off-
spring. The influence of NGS on BD in the clinical
field is reinforcing a growing need for genetic counsel-
ling. Counselling is required to guide and help indivi-
duals and families seeking to determine the causative
genetic bases of their own or a loved one’s disease,
and to apply the proper treatment. It is offered in
order to “avoid maleficence and support autonomy”
[11], and, as such, it reduces the psychological burden
of disclosing untreatable disorders [11]. For instance,
when Hereditary Nonpolyposis Colorectal Cancer
(HNPCC) is suspected, the course of action involves
an extensive process of genetic counselling, and pre-
dictive testing is accepted because an effective course
of action is available [41]. Uncertainties about medical
decisions appear when individuals with a family historyof HNPCC do not show mutations in high-penetrance
genes [41]. The latter situation resembles the circum-
stances that increasingly surround countless medical
conditions with an already “known” genetic back-
ground and it intensifies when – as in many psychi-
atric disorders – there is no precise knowledge of the
underlying causes of the disease, either genetic or
functional.
Two major ethical concerns arise from the use of NGS
for BD in adolescents, as parents and their children are
concurrently involved in making decisions about the right
to know or not to know for each. In this context respect for
children’s own rights needs further attention. As for using
NGS for BD in adults seeking to gain knowledge about
how their genetic makeup may influence their descendants,
the effect of gene-environment interaction, which could be
either positive or negative, and in itself linked to psychiatric
conditions, may need careful consideration to avoid further
discrimination and inappropriate medical conduct. Genetic
counselling will require the allocation of both time and suf-
ficiently trained personnel [11]. To mitigate these needs,
the recourse to group counselling and the use of decision
support services are thought of as reliable substitutes [11].
Lastly, NGS is already being used in pediatric settings
for autosomal and X-linked recessive conditions when
symptoms are suggestive but a clear diagnosis is not
possible [42]. The application of NGS was accepted as
constituting “compassionate use” [42] in a clinical set-
ting for a child of 15 months, and genetic results were
corroborated by sequencing in a licensed clinical labora-
tory [43], as opposed to those obtained through research
methodologies that do not follow standardized proce-
dures. In this example, genetic results were corroborated
by the functional assays followed in research settings
[43], because there was a degree of understanding of the
basic role played by the “new gene” involved. These
examples demonstrate both the need for standardized
procedures to validate results and the need to under-
stand the biological significance of the findings in order
to corroborate the outcomes. It also becomes clear that
collaboration between institutions and their ethics
boards helps support physicians and researchers, while
protecting patients who are research participants.
Concurrently, the use of these technologies gives rise
to a sequence of ethical and social dilemmas, regarding
both the implications of immediate treatment decisions
and the extended meaning of incidental findings and
deterministic life consequences that could ensue [5].
It is reasonable to think that these difficulties will
only be countered with proper regulations – many of
them common to the generalized use of NGS in clinical
settings – with their emphasis on guaranteeing the rights
of all parties involved [11,44]. Delineating the clinical
applications of new genetic technologies may require
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patients and their families, physicians, ethicists and pol-
icymakers [42]. However, the uncertainties are so great,
particularly when dealing with diseases having a multi-
variate component and carrying a strong social stigma,
as is the case with BD, that we believe the process of
developing such regulations may require that researchers
and health professionals consider scientific validation,
clinical utility and prevention or treatment first, whether
with the help of NGS technologies or not, before includ-
ing the opinions of affected patients. Interestingly, when
patients, physicians and the general public were ques-
tioned about the development of pre-symptomatic and
prenatal tests in order to determine attitudes towards
the availability of genetic tests for BD susceptibility
genes, patients and members of the public were in
favour of the development of pre-symptomatic – but not
prenatal – testing. Psychiatrists, who would administer
such tests, appear significantly more cautious, even to-
wards the use of pre-symptomatic genetic testing [38].
Conclusions
We reviewed some major issues surrounding the protec-
tion of NGS research participants, in particular for BD,
yet which are also relevant to other psychiatric condi-
tions. Our analysis included general elements of the con-
sent process, such as comprehension of the research per
se and its associated risks, risks both inherent to the
protocol and derived from omissions in participant pro-
tection safeguards. We also discussed, separately, yet in
the framework of the consent process, the return of indi-
vidual results and incidental findings. Finally, we
explored the issue of autonomy. These three subjects
could and should be further developed, as is the case
with topics such as the safeguarding of privacy, highly
relevant in its own right, due to the amount of informa-
tion generated through NGS, and the use of samples and
data in subsequent, cooperative work.
The topics of our discussion are among the most im-
portant ones for participant protection in the field of
genetic research on mental health, and, as we saw with
the example of BD, highly relevant because of a direct
correlation between participant autonomy, the uncer-
tainties surrounding the causes of such mental health
conditions and the cognitive capacity of the targeted
population. There is a need to regulate the conduct of
research and the subsequent use of data generated
by NGS technologies [3,33]. Regulations should be
developed through the common efforts of researchers,
their institutions, and REBs, on the one hand, and
participants’ representatives, on the other, so as to arrive
at a tailored consent process able to protect those re-
search participants who suffer from, or risk suffering
from, mental health conditions. Active measures, suchas educational activities [26,27], the presence of specially
trained personnel [26], and an increased availability of
genetic counselling can play a decisive role in reinforcing
the autonomy of research participants.
We also examined the role of genetic counselling
when communicating research results and incidental
findings to participants [35], seeing as this process
becomes more demanding with NGS research projects
[3,33]. Applied to genetic psychiatric research, the coun-
selling process has to account for the limitations of
results obtained through NGS technologies, due to the
techniques involved, but also to the multivariate origin
of psychiatric conditions. The counsellor is also faced
with participants’ mixed perceptions and various expec-
tations of research results.
There are emergent clinical applications of NGS. In
the case of BD, and with regard to age of onset,
there exists a need to better determine early warn-
ing signs and improve treatment. We believe this will
affect child, adolescent and adult clinical settings,
with an even greater emphasis on the need for genetic
counselling [11].
While the input of individuals that are directly affected
by a given condition is indispensable, in the case of BD,
as with mental illness in general, researchers need to de-
termine the scientific validity of findings while the pro-
fessionals involved in care and treatment need to
determine both the clinical utility of those results and
their significance for prevention and treatment, and
these priorities should be combined when both groups
collaborate in preparing guidelines and regulations on
using all the data generated by NGS, since this informa-
tion will exert an ongoing influence on the way clinical
practice is carried out.
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